CN112972394A - 一种姜黄素固体分散体及其机械力制备方法 - Google Patents
一种姜黄素固体分散体及其机械力制备方法 Download PDFInfo
- Publication number
- CN112972394A CN112972394A CN202110411442.5A CN202110411442A CN112972394A CN 112972394 A CN112972394 A CN 112972394A CN 202110411442 A CN202110411442 A CN 202110411442A CN 112972394 A CN112972394 A CN 112972394A
- Authority
- CN
- China
- Prior art keywords
- curcumin
- solid dispersion
- preparation
- ball milling
- mechanical force
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 286
- 239000004148 curcumin Substances 0.000 title claims abstract description 142
- 229940109262 curcumin Drugs 0.000 title claims abstract description 142
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 142
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 142
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000000498 ball milling Methods 0.000 claims abstract description 23
- 229910001220 stainless steel Inorganic materials 0.000 claims abstract description 16
- 239000010935 stainless steel Substances 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 13
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 12
- 239000002861 polymer material Substances 0.000 claims abstract description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 11
- 238000007789 sealing Methods 0.000 claims abstract description 4
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 claims description 23
- 229920000858 Cyclodextrin Polymers 0.000 claims description 15
- 229920001277 pectin Polymers 0.000 claims description 15
- 239000001814 pectin Substances 0.000 claims description 15
- 235000010987 pectin Nutrition 0.000 claims description 15
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 14
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 14
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 14
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 14
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 14
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 14
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 11
- 239000001263 FEMA 3042 Substances 0.000 claims description 11
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 11
- 229920002258 tannic acid Polymers 0.000 claims description 11
- 235000015523 tannic acid Nutrition 0.000 claims description 11
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 11
- 229940033123 tannic acid Drugs 0.000 claims description 11
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 229960000502 poloxamer Drugs 0.000 claims description 9
- 229920001983 poloxamer Polymers 0.000 claims description 9
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 8
- 239000001116 FEMA 4028 Substances 0.000 claims description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
- 229960004853 betadex Drugs 0.000 claims description 7
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 5
- 235000013616 tea Nutrition 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 2
- 241000220479 Acacia Species 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 17
- 238000002156 mixing Methods 0.000 abstract description 10
- 230000035699 permeability Effects 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 229920001002 functional polymer Polymers 0.000 abstract description 3
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 238000000034 method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 229960000292 pectin Drugs 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000000227 grinding Methods 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 230000002335 preservative effect Effects 0.000 description 11
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 244000215068 Acacia senegal Species 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000205 acacia gum Substances 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000006070 nanosuspension Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 3
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940075559 piperine Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000823 artificial membrane Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 2
- 235000019100 piperine Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 235000003398 Curcuma aromatica Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005280 amorphization Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- -1 polyphenol compound Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/10—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with one or a few disintegrating members arranged in the container
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110411442.5A CN112972394B (zh) | 2021-04-16 | 2021-04-16 | 一种姜黄素固体分散体及其机械力制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110411442.5A CN112972394B (zh) | 2021-04-16 | 2021-04-16 | 一种姜黄素固体分散体及其机械力制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112972394A true CN112972394A (zh) | 2021-06-18 |
CN112972394B CN112972394B (zh) | 2022-09-13 |
Family
ID=76340837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110411442.5A Active CN112972394B (zh) | 2021-04-16 | 2021-04-16 | 一种姜黄素固体分散体及其机械力制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112972394B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112370442A (zh) * | 2020-12-15 | 2021-02-19 | 浙江工业大学 | 一种辅酶q10药物递送系统及其制备方法 |
CN114469867A (zh) * | 2020-12-15 | 2022-05-13 | 浙江工业大学 | 一种维生素a乙酸酯速释固体分散体的制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1626068A (zh) * | 2003-12-11 | 2005-06-15 | 中国科学院生物物理研究所 | 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法 |
CN101433514A (zh) * | 2008-06-05 | 2009-05-20 | 福建医科大学 | 姜黄素-泊洛沙姆固体分散体及其制备方法与应用 |
CN102470178A (zh) * | 2010-06-25 | 2012-05-23 | 江苏恒瑞医药股份有限公司 | 托伐普坦固体分散体及其制备方法 |
CN106137972A (zh) * | 2016-08-01 | 2016-11-23 | 杭州成邦医药科技有限公司 | 一种含姜黄素的固体分散体及其制备方法 |
CN106692056A (zh) * | 2015-11-18 | 2017-05-24 | 上海本素医药科技有限公司 | 以甘草酸类化合物为膜材的空白脂质体、制备方法及应用 |
CN106793821A (zh) * | 2014-08-29 | 2017-05-31 | 花王株式会社 | 含有难溶性多酚类的固体分散体的制造方法 |
CN108815123A (zh) * | 2018-08-21 | 2018-11-16 | 华南农业大学 | 一种姜黄素固体分散体及其制备方法和应用 |
CN109602708A (zh) * | 2019-01-25 | 2019-04-12 | 南京中医药大学 | 一种无定型姜黄素的固体分散体及其制备方法 |
CN110075071A (zh) * | 2019-05-22 | 2019-08-02 | 中北大学 | 一种姜黄素固体分散体的制备方法 |
WO2020188108A1 (en) * | 2019-03-20 | 2020-09-24 | Anabio Technologies Limited | Microcapsules containing curcumin, and methods for the production thereof |
-
2021
- 2021-04-16 CN CN202110411442.5A patent/CN112972394B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1626068A (zh) * | 2003-12-11 | 2005-06-15 | 中国科学院生物物理研究所 | 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法 |
CN101433514A (zh) * | 2008-06-05 | 2009-05-20 | 福建医科大学 | 姜黄素-泊洛沙姆固体分散体及其制备方法与应用 |
CN102470178A (zh) * | 2010-06-25 | 2012-05-23 | 江苏恒瑞医药股份有限公司 | 托伐普坦固体分散体及其制备方法 |
CN106793821A (zh) * | 2014-08-29 | 2017-05-31 | 花王株式会社 | 含有难溶性多酚类的固体分散体的制造方法 |
CN106692056A (zh) * | 2015-11-18 | 2017-05-24 | 上海本素医药科技有限公司 | 以甘草酸类化合物为膜材的空白脂质体、制备方法及应用 |
CN106137972A (zh) * | 2016-08-01 | 2016-11-23 | 杭州成邦医药科技有限公司 | 一种含姜黄素的固体分散体及其制备方法 |
CN108815123A (zh) * | 2018-08-21 | 2018-11-16 | 华南农业大学 | 一种姜黄素固体分散体及其制备方法和应用 |
CN109602708A (zh) * | 2019-01-25 | 2019-04-12 | 南京中医药大学 | 一种无定型姜黄素的固体分散体及其制备方法 |
WO2020188108A1 (en) * | 2019-03-20 | 2020-09-24 | Anabio Technologies Limited | Microcapsules containing curcumin, and methods for the production thereof |
CN110075071A (zh) * | 2019-05-22 | 2019-08-02 | 中北大学 | 一种姜黄素固体分散体的制备方法 |
Non-Patent Citations (3)
Title |
---|
MUTHU M. J. MOIDEEN ET AL: "Skimmed milk powder and pectin decorated solid lipid", 《J FOOD PROCESS ENG》 * |
QIHONG ZHANG ET AL: "Preparation of curcumin self-micelle solid dispersion with enhanced bioavailability and cytotoxic activity by mechanochemistry", 《DRUG DELIVERY》 * |
菅晓娟: "果胶在结肠靶向给药系统中的应用", 《中国生化药物杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112370442A (zh) * | 2020-12-15 | 2021-02-19 | 浙江工业大学 | 一种辅酶q10药物递送系统及其制备方法 |
CN114469867A (zh) * | 2020-12-15 | 2022-05-13 | 浙江工业大学 | 一种维生素a乙酸酯速释固体分散体的制备方法 |
CN114469867B (zh) * | 2020-12-15 | 2023-04-07 | 浙江工业大学 | 一种维生素a乙酸酯速释固体分散体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112972394B (zh) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ravi et al. | Modified pullulan nanoparticles for oral delivery of lopinavir: Formulation and pharmacokinetic evaluation | |
Tran et al. | Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement | |
CN112972394B (zh) | 一种姜黄素固体分散体及其机械力制备方法 | |
Miller et al. | Drug loading of polymeric micelles | |
US7883723B2 (en) | Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof | |
Sahoo et al. | Oral drug delivery of nanomedicine | |
Lee et al. | Size control of self-assembled nanoparticles by an emulsion/solvent evaporation method | |
CN102327230B (zh) | 一种包裹紫杉烷类药物的蛋白纳米颗粒及其制备方法 | |
JP2012528197A (ja) | ナノダイヤモンド粒子複合体 | |
RU2391966C1 (ru) | Наносистема на основе растительных фосфолипидов для включения биологически активных соединений и способ ее получения (варианты) | |
Shilpi et al. | Improved stability and enhanced oral bioavailability of atorvastatin loaded stearic acid modified gelatin nanoparticles | |
Tang et al. | In situ rapid conjugation of chitosan-gum Arabic coacervated complex with cinnamaldehyde in cinnamon essential oil to stabilize high internal phase Pickering emulsion | |
EP1543841A1 (en) | Soild nano pharmaceutical formulation and preparation method thereof | |
Pandit et al. | Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization | |
WO2011134368A1 (zh) | 果胶-阿霉素轭合物的冻干制剂及制备方法 | |
Jain et al. | Amphotericin B loaded chitosan nanoparticles: implication of bile salt stabilization on gastrointestinal stability, permeability and oral bioavailability | |
CN1698899A (zh) | 以壳聚糖或其衍生物作为药物载体的新型药物组合物 | |
Natesan et al. | The trend of organic based nanoparticles in the treatment of diabetes and its perspectives | |
Hara et al. | Histological examination of PLGA nanospheres for intratracheal drug administration | |
Hirsjärvi et al. | Effect of sugars, surfactant, and tangential flow filtration on the freeze-drying of poly (lactic acid) nanoparticles | |
Purohit et al. | Nanocrystals: a deep insight into formulation aspects, stabilization strategies, and biomedical applications | |
Chavda et al. | Lyotropic liquid crystalline phases: drug delivery and biomedical applications | |
Eilleia et al. | Novel technique of insulin loading into porous carriers for oral delivery | |
CN102357076B (zh) | 一种包裹难溶性药物的蛋白纳米颗粒的制备方法 | |
Pandey et al. | Using 5-fluorouracil-encored plga nanoparticles for the treatment of colorectal cancer: The in-vitro characterization and cytotoxicity studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231214 Address after: Room 510, Building 2, No. 366 Tongyun Street, Liangzhu Street, Yuhang District, Hangzhou City, Zhejiang Province, 310000 Patentee after: Hangzhou Kangling Biotechnology Co.,Ltd. Address before: 325802 2F, No. 251, Haixia village, Longgang City, Wenzhou City, Zhejiang Province Patentee before: Wenzhou Tianju Wanxun Information Technology Co.,Ltd. Effective date of registration: 20231214 Address after: 325802 2F, No. 251, Haixia village, Longgang City, Wenzhou City, Zhejiang Province Patentee after: Wenzhou Tianju Wanxun Information Technology Co.,Ltd. Address before: 310006 No.18 Chaowang Road, Chaohui 6th District, Gongshu District, Hangzhou City, Zhejiang Province Patentee before: JIANG University OF TECHNOLOGY |